文献速递类风湿关节炎脊柱关节炎其他结缔组织病

PD1+TIGIT+ CD4+ T细胞可预测类风湿关节炎和脊柱关节炎对抗TNF治疗的应答

PD1+ TIGIT+ CD4+ T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis.
PubMed 文献 · RMD Open · 2026-05-20

该前瞻性研究纳入67例未使用生物制剂的RA、AS、SjD患者及健康志愿者,用流式细胞术检测CD4和CD8 T细胞上PD-1与TIGIT共表达,并随访抗TNF治疗12个月。基线CD4+PD-1+TIGIT+水平在 future 抗TNF应答者中高于非应答者,且治疗3个月后RA和AS患者中该细胞亚群增加。

要点

  • 基线CD4+PD-1+TIGIT+水平较高与抗TNF应答相关。
  • RA和AS患者抗TNF治疗3个月后CD4和CD8的PD-1+TIGIT+细胞均增加。
  • SjD和RA患者CD8+PD-1+TIGIT+水平高于HV和AS。

核心结论

  • CD4+PD-1+TIGIT+水平在 future 抗TNF应答者中高于非应答者,提示其可能预测抗TNF应答。
  • CD8+PD-1+TIGIT+在SjD和RA中高于HV和AS。
  • RA和AS患者抗TNF治疗3个月后CD4和CD8的PD-1+TIGIT+细胞均增加。

研究设计与样本

  • 前瞻性研究纳入67例未使用生物制剂的RA和AS患者,随访12个月评估抗TNF应答。
  • 基线还纳入SjD患者和健康志愿者(HV)。
  • 用流式细胞术检测基线和抗TNF治疗3个月后CD4和CD8 T细胞的PD-1和TIGIT表达。
  • 用Meso Scale Discovery法检测血浆细胞因子。

主要发现

  • CD8+PD-1+TIGIT+中位水平在RA为24%、SjD为23.2%,高于HV的18.8%和AS的16.2%。
  • SjD患者CD4+PD-1+TIGIT+与循环IgG正相关(r=0.698,p<0.001)。
  • SjD患者CD4+PD-1+TIGIT+与干扰素γ正相关(r=0.635,p=0.017)。
  • SjD患者CD4+PD-1+TIGIT+与IP-10正相关(r=0.612,p=0.005)。
  • 基线CD4+PD-1+TIGIT+水平在 future 抗TNF应答者为9.9%,高于非应答者的6.1%(p=0.003)。

关键数值与推荐

  • RA患者CD8+PD-1+TIGIT+中位水平为24%。
  • SjD患者CD8+PD-1+TIGIT+中位水平为23.2%。
  • HV的CD8+PD-1+TIGIT+中位水平为18.8%。
  • AS患者CD8+PD-1+TIGIT+中位水平为16.2%。
  • 基线CD4+PD-1+TIGIT+在 future 抗TNF应答者为9.9%,非应答者为6.1%(p=0.003)。

临床怎么用

  • 基线CD4+PD-1+TIGIT+水平可能有助于预测RA和AS患者对抗TNF治疗的应答。
  • 抗TNF治疗3个月后CD4和CD8的PD-1+TIGIT+细胞增加,可作为免疫学监测指标。
  • SjD中CD4+PD-1+TIGIT+与IgG、干扰素γ和IP-10相关,提示其与B细胞和干扰素通路活化有关。

局限性

  • 样本量较小(67例),需进一步验证。
  • PD-1+TIGIT+细胞在IMID中的功能作用尚不明确。
  • 研究未报告抗TNF应答的具体定义标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed cell death protein 1 (PD-1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) are immune checkpoints expressed on T cells. Despite recent development of PD-1 agonists in rheumatoid arthritis (RA), little is known about PD-1 and TIGIT coexpression in RA and other immune-mediated inflammatory diseases (IMIDs). This study quantified PD-1 and TIGIT expression in CD4 and CD8 T cells in patients with IMID and examined associations with disease characteristics and anti-tumour necrosis factor (TNF) response. METHODS: Biologics-naïve patients with RA and spondyloarthritis (AS) were followed prospectively to assess anti-TNF response at 12 months. Sjögren's disease (SjD) patients and healthy volunteers (HV) were also included at baseline. PD-1 and TIGIT expression on CD4 and CD8 T cells was analysed by flow cytometry at baseline and after 3 months of anti-TNF treatment. Plasma cytokines were quantified using the Meso Scale Discovery assay. RESULTS: 67 patients were included. Median CD8+PD-1+TIGIT+ levels were higher in RA (24%) and SjD (23.2%) than in HV (18.8%) and AS (16.2%). CD4+PD-1+TIGIT+ were positively correlated with circulating immunoglobulin G (r=0.698, p<0.001), interferon gamma (r=0.635, p=0.017) and IP-10 (r=0.612 p=0.005) levels in patients with SjD. Baseline CD4+PD-1+TIGIT+ levels were higher in future anti-TNF responders (9.9%) compared with non-responders (6.1%, p=0.003). Both CD4+PD-1+TIGIT+ and CD8+PD-1+TIGIT+ cells increased after 3 months of anti-TNF treatment in RA and AS. CONCLUSION: CD8+PD-1+TIGIT+ T-cell expression is elevated in SjD and RA compared with HV and AS. CD4+PD-1+TIGIT+ levels are higher in future anti-TNF responders compared with non-responders and rise after treatment in patients with RA and AS. Further studies should clarify the functional role of CD4+PD-1+TIGIT+ cells in IMIDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Bitoun S, Roulleaux-Dugage M, Naigeon M, et al. PD1+ TIGIT+ CD4+ T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritis. RMD Open. 2026. PMID: 42161414. doi:10.1136/rmdopen-2025-006537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。